Quick-Med Technologies receives Notice of Allowance for MultiStat family of compounds

Quick-Med Technologies, Inc. (OTCBB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that extends the current patent coverage for the Company's MultiStat® family of compounds. The forthcoming patent is part of a portfolio that Quick-Med has licensed from the University of Michigan.

The Notice of Allowance covers patent claims that address methods for treating rosacea with an antimicrobial, a retinoid, and an inhibitor of toll-like receptors in both topical and oral applications. The broad range of antimicrobials to be utilized in combination with the MultiStat family includes tetracycline, erythromycin, azithromycin, clarithromycin, milbemycin, aminoglycoside, penicillin (optimally in combination with a beta-lactamase inhibitor), cephalosporin, fluoroquinolone, streptogramin and sulfanomide.

"Our MultiStat technology has shown to have significant benefit in promoting the maintenance, healing and repair of skin," said J. Ladd Greeno, Quick-Med's CEO. "We are pleased the patent office has issued this Notice of Allowance as it not only strengthens our intellectual property for the cosmetic treatment of rosacea but also adds to our MultiStat patent estate."

A Notice of Allowance communicates the Patent Office's determination that the applicant is entitled to a patent under the law. The Company expects the new patent to be issued later this year.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Critical insights into COVID-19 exposure for healthcare workers